Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Glioblastoma Multiforme Treatment Market

Glioblastoma Multiforme Treatment Market Share

Report ID: GMI9866
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Glioblastoma Multiforme Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture glioblastoma multiforme treatment products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for glioblastoma multiforme treatment.

Glioblastoma Multiforme Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are into clinical phase development. Prominent players operating in the market are as mentioned below:

Amgen Inc.
Amneal Pharmaceuticals
Curtana Pharmaceuticals
Denovo Biopharma
Eisai Co. Ltd. (Gliadel)
F. Hoffmann La Roche Ltd (Genetech USA)
Karyopharm Therapeutics
Merck & Co. Inc.
Novocure GmbH
Pfizer, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global glioblastoma multiforme treatment industry was valued at USD 2.9 billion in 2023 and is anticipated to register 8.6% CAGR between 2024 and 2032 due to the increasing incidence of glioblastoma along with rising awareness and early diagnosis of disease.

The hospitals segment in the market is expected to reach USD 2.5 billion by 2032 due to presence of advanced diagnostic tools, specialized neuro-oncology departments, and clinical trials.

North America glioblastoma multiforme treatment market held 39.5% revenue share in 2023 due to advanced technologies, key pharmaceutical companies, and government cancer research funding.

Amgen Inc., Amneal Pharmaceuticals, Curtana Pharmaceuticals, Denovo Biopharma, Eisai Co. Ltd. (Gliadel), F. Hoffmann La Roche Ltd (Genetech USA), Karyopharm Therapeutics, Merck & Co. Inc., and Novocure GmbH, among others.